Tumor Lysis Risk Stratification and Rasburicase Decisions in Burkitt Lymphoma
A 34-year-old man is diagnosed with Burkitt lymphoma after presenting with a 12-cm abdominal mass and 2 weeks of night sweats. Labs: WBC 46,000/µL with circulating blasts, LDH 4,800 U/L (upper limit of normal 250), uric acid 9.8 mg/dL, potassium 4.9 mEq/L, phosphate 4.1 mg/dL, calcium 9.0 mg/dL, creatinine 1.0 mg/dL. He is scheduled to begin a modified CODOX-M/IVAC regimen tomorrow as an outpatient, and his insurer will not approve inpatient admission without documented medical necessity. He lives 2 hours from the clinic by car. His G6PD status has not been tested.
1. How do you stratify his tumor lysis risk, and what prophylaxis do you start today?
Read the worked answer
He is high risk, not intermediate. Risk factors present:
- Bulky disease (12 cm)
- LDH >2× upper limit of normal (here ~19×)
- Elevated baseline uric acid (9.8 mg/dL)
- High white count with circulating blasts
- A highly chemotherapy-sensitive malignancy (Burkitt lymphoma)
Any one of bulky disease, LDH >2× ULN, or elevated uric acid in a lymphoma with high proliferative rate puts him in the high-risk tier; he has all three. This is a Cairo-Bishop-style stratification and supports the strongest prophylaxis.
Prophylaxis:
- Rasburicase, not allopurinol. Allopurinol blocks new uric acid formation but does nothing about the uric acid already circulating at 9.8 mg/dL; rasburicase degrades existing urate. In high-risk disease, guidelines favor rasburicase.
- Aggressive IV hydration (target roughly 2–3 L/m²/day, titrated to urine output), starting before chemotherapy.
- Do not alkalinize the urine routinely; it promotes calcium phosphate precipitation without clear benefit now that rasburicase is available.
- Strict avoidance of nephrotoxins - no NSAIDs, no contrast unless essential; hold potassium and phosphate in IV fluids.
The G6PD problem, and how to handle it. Rasburicase is contraindicated in G6PD deficiency because it causes severe hemolysis. Send G6PD today. If the result returns within hours, wait for it. If it cannot be obtained in time and chemotherapy cannot be delayed, this is a genuine judgment call: proceed with rasburicase under close hematologic monitoring in a patient without a known high-prevalence ancestry or prior hemolytic history, or use allopurinol plus vigorous hydration if there is a reason to suspect deficiency. Either way, the reasoning and the uncertainty belong in the chart.
The insurance question. Document "high-risk tumor lysis syndrome requiring rasburicase, IV hydration, and electrolyte monitoring at least every 6–8 hours" as the medical necessity; a patient 2 hours from the clinic cannot be safely managed with outpatient labs during the first 24–48 hours of a Burkitt regimen.
2. Twenty-four hours after rasburicase his uric acid reads 0.4 mg/dL. The covering clinician wants to give a second dose. What do you advise?
Read the worked answer
Do not re-dose on the number alone. Rasburicase is a urate oxidase that continues to degrade uric acid in the specimen tube after the blood is drawn. Unless the sample is placed immediately on ice and transported promptly, the measured value is falsely low and does not reflect the patient's in vivo urate. A value of 0.4 mg/dL in that setting is essentially uninterpretable.
Practical sequence:
- Confirm the specimen handling. If the sample was not on ice, treat the result as invalid and redraw properly before making any decision.
- Re-dose based on clinical risk and trajectory, not a single number: rising creatinine, rising potassium or phosphate, or a persistently high-risk clinical picture warrants another dose; a patient with normal renal function, falling LDH, and no electrolyte derangement generally does not.
- Most regimens use rasburicase for a defined short course (often up to 5 days) rather than indefinite daily dosing.
Also reassess the whole panel, not just urate. The endpoints that matter for morbidity are potassium, phosphate, calcium, creatinine, and urine output. Uric acid is a means, not the target.
Explain the reasoning to the team. The failure mode here is a cycle of "number is low, so give more" or its opposite, "number is low, so stop monitoring." Neither follows from a value that may be artificially suppressed. The generalizable point for any exam-style scenario: when a drug degrades its own analyte ex vivo, the assay result must be interpreted with specimen handling in mind.
3. Six hours later: potassium 5.9 mEq/L, phosphate 6.6 mg/dL, calcium 7.4 mg/dL, creatinine 1.8 mg/dL, urine output 20 mL/hr. What is your management?
Read the worked answer
He has laboratory tumor lysis syndrome with early renal compromise. Management is simultaneous, not sequential:
1. Cardiac monitoring now. Hyperkalemia is the acute killer. Get an ECG; if there are peaked T waves, a widened QRS, or any arrhythmia - or if the potassium is rising rapidly - give IV calcium gluconate first for membrane stabilization, then insulin with dextrose to shift potassium intracellularly, and a potassium binder for removal. Do not treat hyperkalemia in TLS with potassium-wasting diuretics if he is oliguric.
2. Hyperphosphatemia. Phosphate binders with meals; avoid any phosphate-containing fluids (check the composition of his IV fluids and any nutrition). Do not give phosphate.
3. Hypocalcemia - treat the patient, not the number. Correct calcium only if he is symptomatic (carpopedal spasm, tetany, seizures, QT prolongation). Giving calcium to a hyperphosphatemic TLS patient risks calcium phosphate precipitation in soft tissue and worsens renal injury.
4. Renal support. Continue high-volume isotonic fluids; if he remains oliguric despite adequate volume, fluids alone will cause overload. A loop diuretic may be tried only once volume status is adequate and only if urine output is not frankly oliguric.
5. Escalate early for dialysis criteria: refractory hyperkalemia, oliguria/anuria with volume overload, severe symptomatic hypocalcemia, or uremia. Call nephrology now rather than at the point of pulmonary edema.
6. Hold nephrotoxins and reassess chemotherapy timing with the treating oncologist. In Burkitt lymphoma the disease itself is the driver, so the answer is rarely to abandon treatment - it is to optimize and proceed with nephrology support. Also recheck the G6PD result if it has now returned.